NYSE: JNJ Q4 earnings rise 49% to $2.10 EPS; oncology and neuroscience lead portfolio momentum

Johnson & Johnson (NYSE: JNJ) reported its fourth-quarter and full-year 2025 earnings, showing that a blend of oncology-led product expansion, neuroscience momentum, and disciplined capital allocation helped the company surpass prior-year benchmarks. For the full year, Johnson & Johnson delivered reported sales of $94.2 billion, representing a 6.0 percent increase compared to 2024. Operational sales rose 5.3 percent, and adjusted operational sales, which strip out the impact of currency and M&A, grew 4.2 percent. Adjusted earnings per share came in at $10.79, up 8.1 percent year-over-year. Fourth-quarter revenue grew 9.1 percent to $24.6 billion, with EPS of $2.10 on a reported basis and $2.46 adjusted. The full-year results also reflect a $(0.10) EPS impact related to the acquisition of Halda Therapeutics.

Beyond its headline numbers, Johnson & Johnson issued full-year 2026 guidance forecasting sales in the range of $100 billion to $101 billion, with the midpoint at $100.5 billion, implying a year-on-year growth of 6.7 percent. The midpoint of adjusted EPS guidance is $11.53, indicating a growth trajectory of approximately 6.9 percent. These results suggest that Johnson & Johnson has not only recovered from its previous earnings troughs but has also entered what Chief Executive Officer Joaquin Duato described as a “catapult year” for innovation-led growth across its core therapeutic and MedTech verticals.

How Johnson & Johnson’s segment-level performance signals a deliberate shift in therapeutic growth priorities

The Innovative Medicine segment closed the year with $60.4 billion in revenue, up 6.0 percent on a reported basis and 5.3 percent operationally. Oncology was the central growth engine, with the franchise delivering $25.4 billion in sales for the year, a 22 percent increase. This was powered by notable expansion in CARVYKTI, DARZALEX, ERLEADA, and the RYBREVANT and LAZCLUZE combination for non-small cell lung cancer. Neuroscience followed as a high-growth contributor, registering 10.1 percent full-year growth, supported by strong performance from CAPLYTA, INVEGA SUSTENNA and TRINZA, and SPRAVATO.

However, the immunology portfolio experienced contraction, primarily due to the steep decline of STELARA following loss of exclusivity. STELARA sales dropped more than 41 percent globally, with over 54 percent year-on-year decline in the United States. This headwind was partially offset by the continued growth of TREMFYA, which delivered $5.2 billion in full-year revenue, up nearly 40 percent, and improved uptake of SIMPONI ARIA in both U.S. and international markets. Despite the immunology drag, the broader franchise resilience demonstrates a successful diversification strategy in play.

Why MedTech’s performance in 2025 suggests a rebalanced growth model driven by cardiovascular and robotics ambitions

MedTech revenue for Johnson & Johnson grew 6.1 percent to $33.8 billion for the full year, with operational growth of 5.4 percent. Cardiovascular solutions emerged as a critical pillar, bolstered by electrophysiology products and the integration of Abiomed and Shockwave Medical. The combination of Abiomed’s heart pump portfolio and Shockwave’s intravascular lithotripsy systems added a material boost to revenue growth, contributing an estimated 1.1 percentage points in operational sales. Notably, the cardiovascular segment alone contributed $8.9 billion in annual revenue.

Advanced surgical and general surgery segments delivered modest growth, while Vision registered a 6.3 percent increase globally. Meanwhile, orthopaedics underperformed relative to the broader MedTech portfolio, delivering just 1.1 percent growth, hampered by operational complexity and restructuring. This lagging performance underscores the rationale behind Johnson & Johnson’s decision to separate the Orthopaedics division, a move that is expected to sharpen focus within the MedTech business and potentially unlock capital efficiency across surgical verticals.

The acquisition of Halda Therapeutics and CAPLYTA integration indicate a bolder play in oncology and neuroscience

Johnson & Johnson’s acquisition of Halda Therapeutics introduced a next-generation oral oncology platform designed to disrupt conventional cancer treatment pathways. Though early in its integration cycle, the acquisition underscores the company’s increasing confidence in platform-driven M&A, particularly in areas where oral therapeutics could rival biologics in convenience and adherence. CAPLYTA, acquired via Intra-Cellular Therapies, added $700 million in annual revenue in its first year under Johnson & Johnson, with $249 million contributed in the fourth quarter alone. Its integration into the neuroscience portfolio has been swift, and it is being positioned as a cornerstone asset for expanding into depressive and mood disorders.

SPRAVATO, the company’s ketamine-derived agent for treatment-resistant depression, recorded $1.7 billion in sales, marking 57.4 percent year-on-year growth. Alongside INVEGA formulations and CAPLYTA, Johnson & Johnson’s neuroscience portfolio is evolving into a high-velocity, high-margin pillar, second only to oncology in terms of therapeutic potential.

How adjusted earnings strength in Q4 creates a clearer base for 2026 valuation

For the fourth quarter of 2025, Johnson & Johnson posted adjusted net earnings of $6 billion, a 21.5 percent year-on-year increase. Adjusted EPS rose 20.6 percent to $2.46. While some of the gains were magnified by a lighter comparable base, particularly due to legal and impairment charges in 2024, the underlying operational momentum remained strong. Research and development spending dropped nearly 15 percent for the year, partly reflecting portfolio rationalization and the completion of several late-stage programs. Gross margins narrowed slightly, with cost of goods sold increasing 10.1 percent, outpacing top-line growth. However, disciplined SG&A spending and a favorable tax environment offset those pressures.

Free cash flow came in stable at approximately $19.7 billion, which supports capital flexibility for both dividend continuity and future bolt-on acquisitions. Management’s FY26 earnings forecast appears calibrated against a more normalized cost base, with limited need for further restructuring except in orthopaedics.

Regulatory milestones and clinical momentum lay the groundwork for mid-term pipeline validation

Johnson & Johnson ended 2025 with multiple FDA approvals and clinical data readouts that could reshape its treatment standards across oncology, neuroscience, and immunology. Approvals for CAPLYTA in major depressive disorder and RYBREVANT FASPRO in combination with LAZCLUZE for first-line NSCLC add commercial levers in neuroscience and lung cancer, respectively. TECVAYLI plus DARZALEX FASPRO demonstrated superior outcomes versus standard of care in relapsed or refractory multiple myeloma, supporting its potential move to earlier lines of therapy.

The company also announced data for CARVYKTI showing lasting treatment-free remissions at 2.5 years and TECVAYLI monotherapy displaying improved progression-free survival even after anti-CD38 therapy. On the regulatory side, Johnson & Johnson submitted its OTTAVA Robotic Surgical System to the U.S. Food and Drug Administration, an event that marks a serious intent to compete in the robot-assisted surgery space. If cleared, OTTAVA would reintroduce competitive dynamics into a space long dominated by Intuitive Surgical.

Execution risks remain but 2026 guidance is broadly credible across therapeutic and MedTech verticals

The midpoint of Johnson & Johnson’s 2026 adjusted EPS guidance of $11.53 represents 6.9 percent growth, tracking slightly ahead of historical five-year compound annual growth rate benchmarks. Sales guidance at the midpoint, $100.5 billion, implies 6.7 percent growth, with operational sales expected to rise between 5.7 and 6.7 percent. Analysts are likely to focus on how the company manages STELARA’s decline, executes the orthopaedics separation cleanly, and delivers on OTTAVA’s potential market entry.

Although geopolitical risks, payer pressures, and currency volatility remain in play, the diversified performance across the Innovative Medicine and MedTech franchises creates a more balanced revenue profile than in previous years. While STELARA erosion continues to pressure immunology, the company’s performance in oncology, neuroscience, and MedTech suggests that Johnson & Johnson is positioning for a more innovation-centric valuation model heading into 2026.

What Johnson & Johnson’s FY25 earnings and FY26 guidance reveal about its competitive positioning and industry direction

• Johnson & Johnson reported FY25 revenue of $94.2 billion and EPS of $11.03, with adjusted EPS of $10.79, reflecting strong year-end momentum and margin discipline.

• Oncology and neuroscience franchises—especially CARVYKTI, DARZALEX, CAPLYTA, and SPRAVATO—drove double-digit growth within Innovative Medicine.

• MedTech saw balanced performance across electrophysiology, Abiomed, and surgical platforms, with early bets like Shockwave delivering outsized returns.

• STELARA’s sharp decline post-LOE dragged immunology, which may continue to weigh on growth until TREMFYA and biosimilar offset strategies mature.

• The OTTAVA Robotic Surgical System FDA submission signals a revived surgical innovation roadmap and direct competition with Intuitive Surgical.

• FY26 guidance of $100.5 billion in sales and $11.53 EPS at the midpoint appears achievable, with a pipeline stacked with late-stage approvals.

• Strategic acquisitions like Halda Therapeutics and integration of CAPLYTA show increased M&A assertiveness, particularly in neuroscience and oral oncology.

• The company’s decision to spin out its Orthopaedics business reflects both structural capital discipline and intent to streamline its MedTech focus.

• Currency and geographic diversification risks remain manageable but require close monitoring amid global macroeconomic shifts.

• Investors are likely to view the report as a stable reset, with clear forward signals—valuation support will depend on execution of pipeline launches and carve-out management.